Drug profile

The FDA adverse-event record for 0.15% Ketoconazole In Usp Trizedta

43 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference 0.15% Ketoconazole In Usp Trizedta. See the species affected, top reactions, and outcomes below.

43
adverse-event reports
0.0%
death-coded share
Dog
most-reported species
11
Loss of hearing - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
43
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

0.15% Ketoconazole In Usp Trizedta

Administration Routes

Auricular (Otic)Unknown

Species Affected

Dog 36
Cat 7

Most Affected Breeds

Retriever - Labrador 7
Retriever - Golden 5
Domestic Shorthair 4
American Pit Bull Terrier 3
Shepherd Dog - German 3
Maltese 2
Chihuahua 2
Siamese 2
Spaniel - King Charles 2
Spaniel (unspecified) 1

Most Reported Reactions

Loss of hearing 11
Head shake - ear disorder 6
Weight loss 5
Ear discharge 5
Ataxia 5
Decreased appetite 4
Third eyelid protrusion 4
Schirmer tear test 4
Deafness 4
Lethargy (see also Central nervous system depression in 'Neurological') 3
Decreased red blood cell count 3
Vomiting 3

Outcome Breakdown

Outcome Unknown
19 (44.2%)
Ongoing
11 (25.6%)
Recovered with Sequela
7 (16.3%)
Recovered/Normal
6 (14.0%)

0.15% Ketoconazole In Usp Trizedta Adverse Event Insights

43 reports name 0.15% Ketoconazole In Usp Trizedta; 0 recorded a death outcome (0.0% of reported events, not a population-level mortality rate). Active ingredient: 0.15% Ketoconazole In Usp Trizedta. Administration routes: Auricular (Otic), Unknown.

By species: Dog (36 reports), Cat (7 reports). By breed: Retriever - Labrador (7), Retriever - Golden (5), Domestic Shorthair (4).

Leading clinical signs: Loss of hearing (11), Head shake - ear disorder (6), Weight loss (5), Ear discharge (5). Outcome, 43 coded reports: Outcome Unknown leads at 44.2%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.